Keytruda (pembrolizumab) / Keytruda Qlex (pembrolizumab + berahyaluronidase alfa) coverage criteria
Customize your policy alerts
Sign up for Anthem Policy CC-0124 alerts
Get alerted when Policy CC-0124 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage criteria for pembrolizumab (Keytruda) and subcutaneous Keytruda Qlex across multiple tumor types, including biomarker and prior‑therapy requirements used for provider requests and prior authorization decisions.
Added Keytruda Qlex step therapy and step therapy table updates.
Added HCPCS J9277 for pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) and removed prior NOC codes C9399 and J9999.
Added quantity limits for Keytruda Qlex vials and dosing frequency.
Coverage Criteria and Indications
Covered indications with criteria (excerpt)
Covered when criteria for Keytruda Qlex step therapy are met
Keytruda Qlex approval conditions
- Exception: Individual unable to use intravenous Keytruda due to no venous access
If exception documented, Keytruda Qlex may be approved
Cutaneous squamous cell carcinoma (cSCC)
Coverage follows FDA-labeled indications and NCCN compendia recommendations as summarized below; biomarker or prior therapy requirements apply where specified.
Tumor-specific examples (present in this document section)
- Breast (TNBC): FDA indication for pembrolizumab in combination with chemotherapy for locally recurrent, unresectable, or metastatic TNBC whose tumors express PD-L1 CPS ≥10; also neoadjuvant combination followed by adjuvant single-agent per FDA.PD-L1 CPS ≥10
- Cervical cancer: FDA indicated for recurrent or metastatic cervical cancer with progression on/after chemotherapy whose tumors express PD-L1 CPS ≥1; indicated in combination with chemotherapy ± bevacizumab and in combination with CRT for FIGO 2014 Stage III-IVA.PD-L1 CPS ≥1
- Esophageal and GEJ cancers: FDA indicated for recurrent locally advanced or metastatic esophageal squamous cell carcinoma with PD-L1 CPS ≥10 after ≥1 prior systemic therapy; also indicated in combination with platinum- and fluoropyrimidine-based chemotherapy for locally advanced or metastatic disease not amenable to surgery/definitive CRT.PD-L1 CPS ≥10 for certain indications
- Gastric/GEJ adenocarcinoma: FDA indicated for recurrent locally advanced or metastatic gastric/GEJ adenocarcinoma with PD-L1 CPS ≥1 after ≥2 prior lines including fluoropyrimidine- and platinum-containing chemotherapy and HER2-targeted therapy if appropriate; also indicated with trastuzumab + platinum/fluoropyrimidine chemo as first-line for HER2+ disease.PD-L1 CPS ≥1
- MSI-H/dMMR and TMB-H tumors: Pembrolizumab is indicated for MSI-H/dMMR tumors (including colorectal and others) and for TMB-H tumors (≥10 mut/Mb) as single-agent therapy in appropriate settings.MSI-H/dMMR or TMB-H (≥10 mut/Mb)
- Cutaneous squamous cell carcinoma: FDA approved for locally advanced, recurrent or metastatic cSCC not curable by surgery or radiation.
- Hodgkin lymphoma: FDA indicated for adults with relapsed or refractory classical Hodgkin lymphoma and pediatrics with refractory cHL or relapse after ≥2 prior lines of therapy.
- Malignant pleural mesothelioma: FDA indicated in combination with pemetrexed and platinum chemotherapy for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma.
Cutaneous squamous cell carcinoma (cSCC)
Covered when ALL of the following are met
Endometrial cancer (recurrent or advanced)
Covered when ALL of the following are met (two pathways)
Tumor-agnostic and other biomarker-driven uses
Covered when ALL of the following are met
Esophageal, esophagogastric junction, and gastric cancers
Covered when criteria are met depending on tumor biomarkers and intent
Head and neck cancers (HNSCC) and nasopharyngeal cancer
Covered when ALL of the following are met
Hepatocellular carcinoma, Hodgkin lymphoma, Kaposi sarcoma, melanoma and other malignancies
Covered when specific indication criteria are met
Melanoma and other listed cancers (BRAF, CNS metastases, MCC, adrenocortical carcinoma)
Covered when specified mutation or clinical context met
Covered Indications and Criteria
Covered when the INDIVIDUAL meets the indication-specific criteria below (many entries require ECOG 0-2, absence of systemic immunosuppressant therapy, and no prior anti–PD-1/PD-L1 exposure unless specified).
The colorectal cancer section specifies that colorectal cancer refers to malignancies of the colon or rectum and does not include anal cancer. Coverage and testing requirements differ by tumor type, so requests for anal canal squamous cell carcinoma should be evaluated under the separate NCCN-referenced anal cancer guidance rather than the colorectal cancer criteria.
For primary mediastinal large B‑cell lymphoma (PMBCL), pembrolizumab is indicated for refractory disease or relapse after two or more prior lines; however, the policy states that pembrolizumab is not recommended for patients who require urgent cytoreductive therapy. Such cases should be managed with urgent cytoreductive approaches rather than checkpoint inhibitor therapy, and requests may be denied if urgent cytoreduction is clinically indicated.
Many indication-specific criteria exclude individuals who are receiving therapy for autoimmune disease or other chronic conditions that require systemic immunosuppressants. In those covered indications the individual must have no concurrent systemic immunosuppressive therapy and generally must not have previously received another anti–PD‑1 or anti–PD‑L1 agent, in order to meet approval criteria.
Uses that do not meet the indication-specific criteria described in this policy are not approved. Specifically, pembrolizumab (Keytruda) is not approved for PMBCL patients who require urgent cytoreductive therapy, and requests that fall outside the documented FDA‑labeled or NCCN‑supported uses may be denied for lack of indication.
The coding lists provided in this document (HCPCS and ICD‑10 ranges) are for informational purposes only. Inclusion of codes does not by itself guarantee member coverage or reimbursement; coverage decisions depend on the member’s contract, documented clinical criteria, and prior authorization determinations.
Document history reflects that the prior indication for small cell lung cancer (SCLC) was removed per FDA withdrawal. The policy history notes SCLC as a removed indication in earlier revisions.
NCCN guidance cautions about use of PD‑1/PD‑L1 inhibitors in primary cutaneous lymphomas (for example, Mycosis Fungoides and Sezary Syndrome). The panel notes theoretical concerns that PD‑1 blockade could accelerate disease in some patients and recommends further study; this implies limited or conditional use rather than routine coverage.
Requests for pembrolizumab may be excluded when the patient’s performance status is outside the referenced ranges (most indications require ECOG 0–2, some permit 0–3) or when the patient is receiving systemic immunosuppressive therapy for autoimmune or chronic conditions. These criteria should be documented in the prior authorization materials and may trigger denial if not met.
Coding section present: HCPCS and ICD‑10 code lists are included elsewhere in this policy and should be used for informational purposes during claims and authorization processes.
Regimens, Combinations, and Special Administration Conditions
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab in combination with pemetrexed and platinum chemotherapy | ||
| First-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma | ||
| Per FDA label: indicated in combination as first-line therapy; coverage requires no prior anti–PD-1/PD-L1 therapy and ECOG 0-2 |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab in combination with gemcitabine and cisplatin | ||
| First-line treatment of locally advanced unresectable or metastatic biliary tract cancer | ||
| FDA‑indicated first‑line regimen; NCCN compendia level 1 recommendation; single‑agent pembrolizumab also supported for MSI‑H/dMMR or subsequent therapy |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab with trastuzumab plus platinum and fluoropyrimidine-based chemotherapy | ||
| First-line treatment of locally advanced unresectable or metastatic HER2‑positive gastric or gastroesophageal junction adenocarcinoma | ||
| Per FDA label: indicated as first‑line therapy for HER2+ disease; PD‑L1 CPS and HER2 status should be documented where applicable |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab in combination with pemetrexed and a platinum agent | ||
| First‑line treatment of metastatic nonsquamous NSCLC without EGFR or ALK genomic tumor aberrations | ||
| FDA‑indicated first‑line combination; requires absence of actionable EGFR/ALK aberrations and ECOG 0‑2; no prior anti‑PD‑1/PD‑L1 therapy for first‑line use |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab in combination with carboplatin plus paclitaxel or nab‑paclitaxel | ||
| First‑line treatment of metastatic squamous NSCLC | ||
| FDA‑indicated first‑line combination; monotherapy option permitted when PD‑L1 TPS ≥50% and chemotherapy is contraindicated (documented) |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab in combination with axitinib or pembrolizumab in combination with lenvatinib | ||
| First‑line or subsequent therapy for advanced renal cell carcinoma per FDA and NCCN guidance (axitinib = FDA first‑line; lenvatinib = NCCN preferred in some settings) | ||
| Coverage aligns with FDA approval for pembrolizumab + axitinib first‑line and NCCN‑endorsed combinations with lenvatinib for relapse/stage IV situations; document regimen and prior anti‑PD‑1/PD‑L1 exposure |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab in combination with ipilimumab (ipilimumab low‑dose when specified) | ||
| Second‑line or subsequent therapy for metastatic or unresectable cutaneous melanoma in selected settings per NCCN | ||
| NCCN lists pembrolizumab + ipilimumab as a preferred second‑line/subsequent option in particular sequences; prior therapy and sequencing rules apply (document BRAF and prior PD‑1 exposure) |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab concurrent with chemoradiotherapy or in combination with specified chemotherapy agents per indication | ||
| Concurrent with chemoradiotherapy for FIGO 2014 Stage III‑IVA cervical cancer and other indication‑specific combinations (e.g., pemetrexed + platinum for mesothelioma; neoadjuvant/adjuvant combinations in NSCLC/HNSCC) | ||
| Coverage contingent on meeting indication‑specific criteria (stage, CRT regimen, no prior anti‑PD‑1/PD‑L1, ECOG 0‑2, and not receiving systemic immunosuppressants) |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab combined with low‑dose ipilimumab (limited doses), or with lenvatinib, or with BRAF/MEK inhibitors (dabrafenib + trametinib) as appropriate | ||
| Melanoma sequencing: second‑line/subsequent combinations for BRAF V600E‑positive disease and other sequencing contexts per NCCN | ||
| Coverage follows NCCN sequencing recommendations: combination with BRAF/MEK for BRAF V600E disease, lenvatinib or low‑dose ipilimumab combinations in defined subsequent‑line settings; prior therapies and mutation status must be documented |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab plus pemetrexed plus a platinum agent | ||
| First‑line treatment of metastatic nonsquamous NSCLC (emphasis on regimen) | ||
| Per FDA label and policy: first‑line combination for nonsquamous NSCLC without actionable molecular markers; ECOG 0‑2 and no prior anti‑PD‑1/PD‑L1 required for first‑line use |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab plus carboplatin plus paclitaxel or nab‑paclitaxel; or pembrolizumab monotherapy when PD‑L1 TPS ≥50% and chemotherapy contraindicated | ||
| First‑line treatment of metastatic squamous NSCLC | ||
| FDA‑indicated first‑line combination; monotherapy allowed for PD‑L1 TPS ≥50% with contraindication to chemo; document PD‑L1 TPS, contraindication rationale, and absence of actionable markers |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab combined with axitinib or lenvatinib | ||
| Advanced renal cell carcinoma — first‑line (axitinib) and NCCN‑preferred combinations (lenvatinib) in relapse/stage IV settings | ||
| Coverage aligns with FDA approval for pembrolizumab + axitinib and NCCN recommendations for pembrolizumab + lenvatinib; document prior anti‑PD‑1 exposure and risk category |
| Regimen | Indication / Line of therapy | Coverage status |
|---|---|---|
| Pembrolizumab monotherapy | ||
| Tumor‑agnostic use for unresectable/metastatic solid tumors with TMB‑H (≥10 mut/Mb) or dMMR/MSI‑H after prior therapy with no satisfactory alternatives | ||
| Per FDA tumor‑agnostic indications: TMB ≥10 mut/Mb or MSI‑H/dMMR required as determined by an FDA‑approved test; Karnofsky ≥70% and documentation of prior therapies and lack of alternatives |
| Regimen | Condition for Keytruda Qlex | Coverage status |
|---|---|---|
| Keytruda Qlex (SC pembrolizumab + berahyaluronidase alfa) substitution for IV pembrolizumab | ||
| May be approved when the individual is unable to use intravenous Keytruda due to no venous access; step therapy with preferred agents may apply | ||
| Policy adds step therapy for Keytruda Qlex: approval permitted if documented inability to use IV pembrolizumab (no venous access); otherwise trial of preferred agent(s) may be required per benefit plan |
| Revision summary | Examples mentioned | Coverage status |
|---|---|---|
| Policy history — regimen updates summarized | ||
| Document history records multiple updates adding combinations (e.g., carboplatin/paclitaxel combos, lenvatinib combinations, enfortumab vedotin combinations) and operational changes such as Keytruda Qlex step therapy and coding updates | ||
| See document history entries for dates and specific changes (multiple revisions listed in history) — specific regimen criteria remain in indication sections |
| Example added combination | Tumor type / Context | Coverage status |
|---|---|---|
| Pembrolizumab with platinum and fluoropyrimidine‑based chemotherapy (± trastuzumab) | ||
| Esophageal or gastric/GEJ adenocarcinoma first‑line (HER2+ when trastuzumab included) | ||
| Added per FDA label and NCCN guidance as noted in document history; PD‑L1 CPS and HER2 status documentation required where applicable |
Prior Authorization, Documentation, and Step Therapy
Prior authorization required
Prior authorization is required for use of Keytruda (pembrolizumab) or Keytruda Qlex consistent with this policy; approval decisions will reference FDA-labeled indications and NCCN compendia recommendations summarized in the document.
Verify biomarkers and line of therapy
Prior authorization must confirm biomarker status and line-of-therapy where applicable (for example: PD-L1 TPS/CPS, EGFR/ALK negative status in NSCLC, MSI-H/dMMR, or TMB ≥10 mut/Mb) and that use aligns with the labeled or guideline-supported line of therapy.
Prior authorization per indication-specific criteria
Prior authorization determinations are made per the indication-specific criteria in the policy and require documentation of diagnosis, combination therapy details, biomarker status, prior treatments, and ECOG performance status where specified.
Keytruda Qlex prior authorization and step therapy
When Keytruda Qlex is being requested, prior authorization applies and the benefit plan may impose step therapy requiring trial of preferred agent(s) before approving Keytruda Qlex.
Preferred-agent trial may be required before Keytruda Qlex
Approval of Keytruda Qlex may require documented trial of a preferred pembrolizumab product unless an exception applies; preferred agents are those deemed clinically comparable and preferred for clinical evidence and cost-effectiveness.
- Preferred products list referenced in policy.
- Exception allowed if patient is unable to use IV Keytruda due to no venous access.
Benefit and prior authorization status varies by plan
Benefit designation and prior authorization status differ by plan and effective dates: Keytruda is listed as Preferred and Keytruda Qlex as Non-Preferred on the specified Commercial, Medicaid, and Medicare effective dates.
Document prior therapy sequencing
For certain indications, pembrolizumab use is contingent on prior therapies; documentation must show progression on or intolerance to specified prior systemic therapies before pembrolizumab is authorized.
NSCLC: platinum progression/intolerance and targeted therapy sequencing
For NSCLC single-agent indications (TPS ≥1% after platinum chemotherapy), prior progression on or intolerance to platinum-containing chemotherapy must be documented; patients with EGFR/ALK aberrations must have progressed on approved targeted therapy first.
Follow indication-specific sequencing and prior therapy rules
Some indications specify prior lines of therapy (for example: subsequent therapy in dMMR/MSI-H colorectal cancer after oxaliplatin/irinotecan/fluoropyrimidine), and prior exposure to nivolumab or pembrolizumab may preclude approval unless allowed by the indication.
Approval if IV Keytruda cannot be used (no venous access)
Keytruda Qlex may be approved if the individual is unable to use intravenous Keytruda due to lack of venous access; documentation of inability to use IV Keytruda is required to support approval.
- Document inability to use IV administration (e.g., no venous access).
- Specify requested Keytruda Qlex vial strength and dosing interval per quantity limits.
Keytruda Qlex requires preferred-agent trial unless IV contraindicated
Keytruda Qlex is subject to step therapy: approval generally requires prior use of a preferred agent unless the patient is unable to use IV Keytruda (documented no venous access).
Plan utilization management may take precedence
Plan-level utilization management programs or other plan policies may impose step therapy or other requirements that take precedence over the clinical criteria in this policy.
Provide PD-L1 / MSI / TMB biomarker results when required
Where an FDA indication or NCCN recommendation requires biomarkers, documentation of tumor PD-L1 status (e.g., CPS or TPS), MSI/MMR, or TMB results must be provided with the prior authorization request.
Include specific biomarker details (TPS, EGFR/ALK, MSI/dMMR, TMB)
Required biomarker documentation should include PD-L1 TPS where relevant, EGFR/ALK genomic status for NSCLC, and MSI-H/dMMR or TMB-H status (TMB ≥10 mut/Mb) when claiming biomarker-based indications.
Submit diagnosis, prior therapies, biomarkers, and performance status
Clinical documentation must include diagnosis, line of therapy, prior therapies, relevant biomarker status (dMMR/MSI-H, PD-L1 CPS/TPS, TMB, POLE/POLD1 where relevant), ECOG performance status, and whether prior anti–PD-1/PD-L1 therapy was given.
Show patient meets indication-specific clinical thresholds
Documentation provided with the request must demonstrate the patient meets the indication-specific criteria described in the policy, including ECOG or Karnofsky performance thresholds and other case-specific requirements.
Document inability to use IV Keytruda and requested Qlex dosing
For Keytruda Qlex requests, include documentation supporting inability to use IV Keytruda (for example, no venous access) and indicate the requested Keytruda Qlex vial strength and dosing interval per stated quantity limits.
- State evidence of no venous access.
- Specify 395 mg per 21 days or 790 mg per 42 days vial strength requested as applicable.
Use cited literature and package inserts to support requests
References cited in the policy—such as package inserts, KEYNOTE trials, and NCCN guidelines—may be used to support the clinical rationale provided with prior authorization requests.
Requests outside labeled or compendia uses may be denied
Requests for use that do not match FDA-labeled indications or NCCN compendia uses outlined in this document may be denied for lack of documented indication.
PMBCL with urgent cytoreductive need may be denied
Keytruda is not recommended for PMBCL patients who require urgent cytoreductive therapy; such cases may be denied if urgent cytoreduction is clinically required.
Performance status and prior anti–PD-1/PD-L1 therapy considerations
Most indications require ECOG performance status 0–2 (some allow 0–3); requests where the beneficiary's performance status is outside the referenced ranges or where prior anti–PD-1/PD-L1 therapy contradicts the indication may be denied.
Concurrent systemic immunosuppression exclusion
Use in patients receiving systemic immunosuppressant therapy or active autoimmune disease therapy is excluded in many indications and may trigger denial of the request.
Denial triggers for unmet criteria or missing documentation
Requests that do not meet the specified indication criteria (including PMBCL requiring urgent cytoreductive therapy) or lack required documentation may not be approved.
Keytruda Qlex may be denied if IV Keytruda is feasible
If the individual can use IV Keytruda, requests for Keytruda Qlex may be denied—an exception applies only when inability to use IV Keytruda (e.g., no venous access) is documented.
Legal/contractual and plan UM precedence
Federal or state laws, contract language, and Plan utilization management programs or policies may take precedence over this clinical criteria and affect authorization decisions.
Billing and Diagnosis Codes
| No codes listed |
| C00.0-C15.9 | Malignant neoplasms of head and neck |
| C16.0-C21.8 | Malignant neoplasms of stomach, intestines, rectum, anus |
| C22.0-C22.1 | Liver cell, intrahepatic bile duct carcinoma |
| C22.3 | Angiosarcoma of liver |
| C22.8-C24.9 | Malignant neoplasms of liver, gallbladder, other and unspecified parts of biliary tract |
| C25.0-C25.9 | Malignant neoplasm of pancreas |
| C26.0 | Malignant neoplasm of intestinal tract, part unspecified |
| C30.0-C31.9 | Malignant neoplasm of nasal cavity, accessory sinuses |
| C32.0-C34.92 | Malignant neoplasm of larynx, trachea, bronchus and lung |
| C37 | Malignant neoplasm of thymus |
| C43.0-C43.8 | ICD-10-CM codes added for melanoma (per document history) |
| C64.1-C64.9 | ICD-10-CM codes for kidney cancer (noted in history; added/removed in various revisions) |
| C15.3-C15.5, C15.8, C15.9, C16.0 | ICD-10-CM codes for esophageal cancer (per document history) |
| C50.01-C50.919 | ICD-10-CM breast cancer codes (added Dec 2020) |
| D09.0-D09.19 | ICD-10 codes for non-invasive bladder lesions (added Feb 2020) |
Line of Therapy Designations by Indication
Biomarker Thresholds and Testing Requirements
Definitions and Key Terms
Background: Pembrolizumab is a programmed death‑1 (PD‑1) blocking monoclonal antibody used across a broad range of solid tumors and certain hematologic malignancies. Keytruda Qlex is a subcutaneous formulation that combines pembrolizumab with berahyaluronidase alfa to enable subcutaneous administration and may be considered when intravenous administration is not possible.
Keytruda Qlex Special Conditions and Regimen Exceptions
Keytruda Qlex step therapy & exceptions
Step therapy requirement
Exception to step therapy
Quantity limits and coding notes
Background and Scope
Pembrolizumab (Keytruda) is an anti–PD‑1 monoclonal antibody with FDA‑approved indications in multiple tumor types and recognized uses in NCCN compendia. Its indications and use criteria in this policy are aligned with FDA labeling and guideline recommendations, including biomarker‑driven indications such as MSI‑H/dMMR and TMB‑H where applicable.
Scope summary: Pembrolizumab is used in both first‑line and subsequent‑line settings depending on tumor type and biomarker status. Examples include first‑line combinations with chemotherapy for NSCLC, gastric, or mesothelioma, and subsequent‑line single‑agent use for MSI‑H/dMMR or TMB‑H tumors and relapsed/refractory Hodgkin lymphoma. Specific line‑of‑therapy requirements are indication dependent and must be documented.
Policy Revision History
Added Keytruda Qlex step therapy and updated the step therapy table to operationalize preferred agent requirements and exceptions for inability to use IV Keytruda (e.g., no venous access).
Added pembrolizumab use in combination with paclitaxel and a platinum agent, with or without bevacizumab, for cervical cancer; added combination use with platinum and fluoropyrimidine-based chemotherapy for esophageal cancer; added combination with trastuzumab plus platinum and fluoropyrimidine for gastric/GEJ HER2-positive disease—documented in policy history as regimen additions and clarifications.
Added criteria for pembrolizumab in combination with lenvatinib for advanced endometrial carcinoma (pMMR) per FDA label and combination use with Inlyta (axitinib) in select sarcoma indications—recorded in the document history.
Added FDA indication for malignant pleural mesothelioma in combination with pemetrexed and platinum as first-line therapy; coding updates reflected in document history.
Document history entry notes removal of the small cell lung cancer (SCLC) indication following FDA withdrawal; reviewers should reference the policy history for prior timeline details and prior-coded changes related to SCLC.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.